What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

1. ESR Essentials: imaging of lymphoma-practice recommendations by the European Society of Oncologic Imaging.European radiology · 2025
   Guideline
2. Mapping the research landscape of PET/CT in lymphoma: insights from a bibliometric analysis.Frontiers in oncology · 2025
   Pooled it
3. Chemokine receptor-4 targeted PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2020
   Trial
4. Radiometabolic Therapy in Lymphoma: From Radioimmunotherapy to Emerging Theranostic and Combination Strategies.Cancers · 2026
   Review
5. Optimization of next-generation CXCR4 ligands for radiotheranostic applications.Frontiers in pharmacology · 2026
   Review
6. The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025).Theranostics · 2026
   Review
7. Establishment and validation of a clinical threshold criteria for choosing PET imaging tracers for indolent non-Hodgkin's lymphoma.EJNMMI research · 2025
   Article
8. Selective PET imaging of CXCR4 using the AlEuropean journal of nuclear medicine and molecular imaging · 2025
   Article
9. Molecular Imaging of Cancer Stem Cells and Their Role in Therapy Resistance.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
   Review
10. The Clinical Role of CXCR4-Targeted PET on Lymphoproliferative Disorders: A Systematic Review.Journal of clinical medicine · 2024
    Review
11. Nanobiotechnology augmented cancer stem cell guided management of cancer: liquid-biopsy, imaging, and treatment.Journal of nanobiotechnology · 2024
    Review
12. Advances in PET Imaging of the CXCR4 Receptor: [Seminars in nuclear medicine · 2024
    Review
13. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime.Nature reviews. Clinical oncology · 2023
    Review
14. Bing-Neel Syndrome and Coexisting Pituitary Macroadenoma in a Patient with Waldenström Macroglobulinemia Revealed byDiagnostics (Basel, Switzerland) · 2023
    Article
15. FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects.Cancers · 2023
    Review
16. CXCR4-targeted theranostics in oncology.European journal of nuclear medicine and molecular imaging · 2022
    Review
17. The Role of [Cancers · 2022
    Review
18. Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach followingExpert review of hematology · 2022
    Review
19. CXCR4-Directed PET/CT with [Molecular imaging and biology · 2022
    Article
20. CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication.Blood · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as